Class IIa HDAC Inhibitors for Selective Neurodegenerative Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions mediated by histone deacetylases (HDACs) lack effective inhibitors that can selectively target specific HDAC classes, such as Class IIa HDACs, which are involved in various diseases including neurodegenerative disorders, fibrosis, and cancer, without significant side effects.
Innovation Solution
Development of specific HDAC inhibitors, represented by compounds of Formula I and their pharmaceutically acceptable salts, which selectively inhibit Class IIa HDACs, including HDAC-4 and HDAC-5, by administering a therapeutically effective amount to treat conditions like neurodegenerative diseases, fibrosis, and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HDAC inhibitors are used to treat conditions mediated by histone deacetylases, then therapeutic effects are achieved, but selectivity for specific HDAC classes (such as Class IIa) is insufficient leading to significant side effects
Solution Approach 1:
The patent segments the HDAC enzyme family into different classes (Class I, IIa, IIb, IV) and develops inhibitors that specifically target Class IIa HDACs (HDAC4, HDAC5, HDAC7, HDAC9) while sparing other classes. This selective inhibition approach divides the broad HDAC inhibition effect into class-specific actions, thereby achieving therapeutic benefits for conditions like neurodegenerative disorders and fibrosis while minimizing off-target side effects associated with non-selective HDAC inhibition
Solution Approach 2:
The patent applies local quality by designing inhibitors with specific molecular structures (compounds of Formula I featuring hydroxamic acid or oxyamino amide groups) that exhibit preferential binding affinity for Class IIa HDACs. This localized specificity ensures that the therapeutic action is concentrated on the target enzyme class responsible for particular pathologies, while other HDAC classes continue their normal physiological functions without disruption
2Adaptability or versatility
If non-selective HDAC inhibitors are used to achieve broad therapeutic coverage, then multiple conditions may be treated, but specificity for target enzymes is reduced causing adverse effects
Solution Approach 1:
Rather than using a single non-selective inhibitor, the patent segments the HDAC family into targetable classes and develops Class IIa-selective compounds. This segmentation allows the treatment to be adapted specifically for conditions driven by Class IIa HDAC dysregulation (such as neurodegenerative diseases, fibrosis, and certain cancers) while maintaining high enzyme specificity and avoiding the adverse effects of broad-spectrum HDAC inhibition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit Class IIa HDACs, providing therapeutic benefits for conditions like Alzheimer's disease, fibrosis, and cancer by selectively targeting these enzymes, thereby offering a more precise treatment approach compared to existing therapies.
Implementation Method 1
Histone deacetylases (HDACs) are zinc-containing enzymes which catalyse the removal of acetyl groups from the ε-amino termini of lysine residues clustered near the amino terminus of nucleosomal histones
Data Source
AI summary
Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.